Angela J Frank1, B Taylor Thompson. 1. Pulmonary and Critical Care Unit, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.
Abstract
PURPOSE OF REVIEW: Studies of the pharmacologic management of acute respiratory distress syndrome (ARDS) have yielded conflicting results. The purpose of this review is to discuss recent pharmacologic trials in ARDS, using the conceptual framework of ARDS as a heterogeneous disease. RECENT FINDINGS: Whereas most drug trials in ARDS have been negative, some studies suggest that targeting therapies at subgroups of patients may be successful. Proposed subgroups include early versus late-phase ARDS, direct versus indirect lung injury, and patients with altered coagulation. Corticosteroids have beneficial short-term effects when given at low or moderate doses sooner than 2 weeks but appear to be harmful if initiated later and are of unclear benefit if lung protective ventilation is also used. Surfactant may be helpful in patients with direct lung injury. Anticoagulants and vasodilators may have a greater chance for success in the subset of patients with vascular disease and a high dead-space fraction may identify such a population. SUMMARY: ARDS is a heterogeneous syndrome. Failure to target subgroups more likely to benefit from specific therapies may be one explanation for largely disappointing trial results so far.
PURPOSE OF REVIEW: Studies of the pharmacologic management of acute respiratory distress syndrome (ARDS) have yielded conflicting results. The purpose of this review is to discuss recent pharmacologic trials in ARDS, using the conceptual framework of ARDS as a heterogeneous disease. RECENT FINDINGS: Whereas most drug trials in ARDS have been negative, some studies suggest that targeting therapies at subgroups of patients may be successful. Proposed subgroups include early versus late-phase ARDS, direct versus indirect lung injury, and patients with altered coagulation. Corticosteroids have beneficial short-term effects when given at low or moderate doses sooner than 2 weeks but appear to be harmful if initiated later and are of unclear benefit if lung protective ventilation is also used. Surfactant may be helpful in patients with direct lung injury. Anticoagulants and vasodilators may have a greater chance for success in the subset of patients with vascular disease and a high dead-space fraction may identify such a population. SUMMARY: ARDS is a heterogeneous syndrome. Failure to target subgroups more likely to benefit from specific therapies may be one explanation for largely disappointing trial results so far.
Authors: Carolyn S Calfee; Kevin Delucchi; Polly E Parsons; B Taylor Thompson; Lorraine B Ware; Michael A Matthay Journal: Lancet Respir Med Date: 2014-05-19 Impact factor: 30.700
Authors: Heather Lynn; Xiaoguang Sun; Nancy Casanova; Manuel Gonzales-Garay; Christian Bime; Joe G N Garcia Journal: Antioxid Redox Signal Date: 2019-06-18 Impact factor: 8.401
Authors: Hallie C Prescott; Carolyn S Calfee; B Taylor Thompson; Derek C Angus; Vincent X Liu Journal: Am J Respir Crit Care Med Date: 2016-07-15 Impact factor: 21.405
Authors: Ednan K Bajwa; Cindy K Malhotra; B Taylor Thompson; David C Christiani; Michelle N Gong Journal: Crit Care Med Date: 2012-05 Impact factor: 7.598
Authors: Zhiguo Zhao; Nancy Wickersham; Kirsten N Kangelaris; Addison K May; Gordon R Bernard; Michael A Matthay; Carolyn S Calfee; Tatsuki Koyama; Lorraine B Ware Journal: Intensive Care Med Date: 2017-06-07 Impact factor: 17.440
Authors: Ruyang Zhang; Zhaoxi Wang; Paula Tejera; Angela J Frank; Yongyue Wei; Li Su; Zhaozhong Zhu; Yichen Guo; Feng Chen; Ednan K Bajwa; B Taylor Thompson; David C Christiani Journal: Intensive Care Med Date: 2016-12-28 Impact factor: 17.440